Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and a pioneer in the emerging field of molecular medicine. The Company is focused on the discovery and development of therapeutic radiopharmaceuticals and targeted molecular imaging agents for use in oncology and cardiology.
Biopharmaceutical
Elan Drug Technologies (EDT) is the world’s leading drug delivery company and is a business unit of Elan (NYSE:ELN). The company focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry. Their NanoCrystal® technology is a proven innovation for poorly water-soluble compounds, manufactured to the nanoscale it has five licensed products commercialized to date.
BioTrove, Inc. provides micro and nano-scale technology platforms for life science and drug discovery research applications.
Ablynx is focused on the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious life-threatening human diseases. Ablynx is developing a portfolio of Nanobody®-based therapeutic programmes in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. The unique structure and stability of Nanobodies® has allowed Ablynx, and its partners, to pursue targets that are typically difficult to reach with conventional antibodies.